Angelo Antonini
#127,498
Most Influential Person Now
Researcher
Angelo Antonini's AcademicInfluence.com Rankings
Angelo Antoninichemistry Degrees
Chemistry
#2882
World Rank
#3851
Historical Rank
Organic Chemistry
#446
World Rank
#521
Historical Rank
Angelo Antoninibiology Degrees
Biology
#8171
World Rank
#11208
Historical Rank
Molecular Biology
#1012
World Rank
#1036
Historical Rank
Neuroscience
#1113
World Rank
#1155
Historical Rank
Download Badge
Chemistry Biology
Angelo Antonini's Degrees
- PhD Neuroscience University of Milan
- Bachelors Chemistry University of Bologna
Why Is Angelo Antonini Influential?
(Suggest an Edit or Addition)Angelo Antonini's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- The PRIAMO study: A multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson's disease (2009) (1167)
- Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria (2017) (1150)
- Valvular heart disease and the use of dopamine agonists for Parkinson's disease. (2007) (652)
- Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double-dummy study (2014) (524)
- EFNS/MDS‐ES recommendations for the diagnosis of Parkinson's disease (2013) (355)
- Metabolic hyperfrontality and psychopathology in the ketamine model of psychosis using positron emission tomography (PET) and [18F]fluorodeoxyglucose (FDG) (1997) (350)
- Patterns of regional brain activation associated with different forms of motor learning (2000) (339)
- Parkinson's disease: the non-motor issues. (2011) (332)
- Striatal glucose metabolism and dopamine D2 receptor binding in asymptomatic gene carriers and patients with Huntington's disease. (1996) (323)
- Functional brain networks in DYT1 dystonia (1998) (316)
- Levodopa in the treatment of Parkinson’s disease: an old drug still going strong (2010) (256)
- Intrajejunal levodopa infusion in Parkinson's disease: A pilot multicenter study of effects on nonmotor symptoms and quality of life (2009) (254)
- Pramipexole versus sertraline in the treatment of depression in Parkinson’s disease (2006) (242)
- Duodenal levodopa infusion for advanced Parkinson's disease: 12‐month treatment outcome (2007) (241)
- Complementary PET studies of striatal neuronal function in the differential diagnosis between multiple system atrophy and Parkinson's disease. (1997) (240)
- Pain as a nonmotor symptom of Parkinson disease: evidence from a case-control study. (2008) (235)
- Parkinson's disease tremor-related metabolic network: Characterization, progression, and treatment effects (2011) (215)
- Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson's disease (2007) (212)
- Long‐term changes of striatal dopamine D2 Receptors in patients with Parkinson's disease: A study with positron emission tomography and [11C]Raclopride (1997) (205)
- The progression of non-motor symptoms in Parkinson’s disease and their contribution to motor disability and quality of life (2012) (202)
- EuroInf: A Multicenter Comparative Observational Study of Apomorphine and Levodopa Infusion in Parkinson's Disease (2015) (202)
- Gender-related differences in the burden of non-motor symptoms in Parkinson’s disease (2012) (196)
- Cognitive impairment in multiple system atrophy: A position statement by the neuropsychology task force of the MDS multiple system atrophy (MODIMSA) study group (2014) (193)
- The G6055A (G2019S) mutation in LRRK2 is frequent in both early and late onset Parkinson’s disease and originates from a common ancestor (2005) (191)
- Effect of age on D2 dopamine receptors in normal human brain measured by positron emission tomography and 11C-raclopride. (1993) (187)
- Complementary positron emission tomographic studies of the striatal dopaminergic system in Parkinson's disease. (1995) (182)
- Metabolic network abnormalities in early Huntington's disease: an [(18)F]FDG PET study. (2001) (182)
- [11C]raclopride and positron emission tomography in previously untreated patients with Parkinson's disease (1994) (178)
- Outcome of Parkinson's Disease Patients Affected by COVID‐19 (2020) (177)
- T2 relaxation time in patients with Parkinson's disease (1993) (173)
- Comprehensive analysis of the LRRK2 gene in sixty families with Parkinson's disease (2006) (170)
- Adherence to antiparkinson medication in a multicenter European study (2009) (167)
- Positron emission tomographic studies in restless legs syndrome (1999) (166)
- A reassessment of risks and benefits of dopamine agonists in Parkinson's disease (2009) (163)
- Mesiobasal versus lateral temporal lobe epilepsy (1993) (162)
- The metabolic anatomy of Tourette's syndrome (1997) (160)
- King's Parkinson's disease pain scale, the first scale for pain in PD: An international validation (2015) (158)
- Radiological biomarkers for diagnosis in PSP: Where are we and where do we need to be? (2017) (158)
- Dopamine transporter imaging with fluorine-18-FPCIT and PET. (1998) (153)
- The relationship between impulsivity and impulse control disorders in Parkinson's disease (2008) (151)
- Identification of circulating microRNAs for the differential diagnosis of Parkinson's disease and Multiple System Atrophy (2014) (147)
- The metabolic topography of essential blepharospasm (2000) (145)
- Rotigotine and specific non-motor symptoms of Parkinson's disease: post hoc analysis of RECOVER. (2013) (145)
- Collective physician perspectives on non-oral medication approaches for the management of clinically relevant unresolved issues in Parkinson's disease: Consensus from an international survey and discussion program. (2015) (144)
- Networks mediating the clinical effects of pallidal brain stimulation for Parkinson's disease: a PET study of resting-state glucose metabolism. (2001) (144)
- Non-motor symptoms in atypical and secondary parkinsonism: the PRIAMO study (2009) (141)
- Reduced dopamine transporter density in the ventral striatum of patients with Parkinson's disease and pathological gambling (2010) (141)
- Functional abnormalities underlying pathological gambling in Parkinson disease. (2008) (140)
- Impulsivity and compulsivity in drug‐naïve patients with Parkinson's disease (2011) (140)
- Clinical and neuropsychological follow up at 12 months in patients with complicated Parkinson’s disease treated with subcutaneous apomorphine infusion or deep brain stimulation of the subthalamic nucleus (2006) (139)
- Dynamic functional connectivity changes associated with dementia in Parkinson's disease. (2019) (136)
- 123I-Ioflupane/SPECT binding to striatal dopamine transporter (DAT) uptake in patients with Parkinson’s disease, multiple system atrophy, and progressive supranuclear palsy (2003) (132)
- Metabolic correlates of pallidal neuronal activity in Parkinson's disease. (1997) (129)
- Cerebral glucose metabolism in women with panic disorder. (1998) (128)
- Regulation of ER‐mitochondria contacts by Parkin via Mfn2 (2018) (124)
- MR imaging of the superior profile of the midbrain: differential diagnosis between progressive supranuclear palsy and Parkinson disease. (2004) (122)
- Reproducibility of regional metabolic covariance patterns: comparison of four populations. (1999) (122)
- Levodopa-carbidopa intestinal gel in advanced Parkinson's: Final results of the GLORIA registry. (2017) (121)
- A 5-year prospective assessment of advanced Parkinson disease patients treated with subcutaneous apomorphine infusion or deep brain stimulation (2011) (121)
- Global long-term study on motor and non-motor symptoms and safety of levodopa-carbidopa intestinal gel in routine care of advanced Parkinson's disease patients; 12-month interim outcomes. (2015) (120)
- Functional correlates of pallidal stimulation for Parkinson's disease (2001) (120)
- Developing consensus among movement disorder specialists on clinical indicators for identification and management of advanced Parkinson’s disease: a multi-country Delphi-panel approach (2018) (119)
- Selecting deep brain stimulation or infusion therapies in advanced Parkinson’s disease: an evidence-based review (2013) (118)
- [11C]Raclopride‐PET studies of the Huntington's disease rate of progression: Relevance of the trinucleotide repeat length (1998) (112)
- Chronic subcutaneous infusion therapy with apomorphine in advanced Parkinson's disease compared to conventional therapy: a real life study of non motor effect. (2011) (110)
- Pathological gambling in patients with Parkinson's disease is associated with fronto‐striatal disconnection: A path modeling analysis (2011) (110)
- Early DEtection of wEaring off in Parkinson disease: the DEEP study. (2014) (108)
- Which ante mortem clinical features predict progressive supranuclear palsy pathology? (2017) (108)
- The metabolic anatomy of tremor in Parkinson's disease (1998) (106)
- LRRK2 G2019S mutation and Parkinson's disease: a clinical, neuropsychological and neuropsychiatric study in a large Italian sample. (2006) (105)
- Tolerability of paroxetine in Parkinson's disease: A prospective study (2000) (105)
- Validation of the Italian version of the Movement Disorder Society—Unified Parkinson’s Disease Rating Scale (2013) (103)
- Duodenal Levodopa Infusion Improves Quality of Life in Advanced Parkinson’s Disease (2008) (103)
- Cognitive decline in Parkinson’s disease: the complex picture (2016) (103)
- Randomized study of sertraline and low‐dose amitriptyline in patients with Parkinson's disease and depression: Effect on quality of life (2006) (101)
- Differential diagnosis of parkinsonism with [18F]fluorodeoxyglucose and PET (1998) (101)
- Peripheral neuropathy in Parkinson's disease: levodopa exposure and implications for duodenal delivery. (2013) (100)
- Role of DAT‐SPECT in the diagnostic work up of Parkinsonism (2007) (99)
- EuroInf 2: Subthalamic stimulation, apomorphine, and levodopa infusion in Parkinson's disease (2019) (99)
- Wearable sensor-based objective assessment of motor symptoms in Parkinson’s disease (2015) (99)
- Medical and surgical management of advanced Parkinson's disease (2018) (98)
- ICARUS study: prevalence and clinical features of impulse control disorders in Parkinson’s disease (2017) (97)
- MMSE and MoCA in Parkinson’s disease and dementia with Lewy bodies: a multicenter 1-year follow-up study (2016) (95)
- A Proposal for a Comprehensive Grading of Parkinson's Disease Severity Combining Motor and Non-Motor Assessments: Meeting an Unmet Need (2013) (93)
- Wearing‐off scales in Parkinson's disease: Critique and recommendations (2011) (92)
- Early-onset parkinsonism associated with PINK1 mutations (2005) (91)
- Clinical correlates and cognitive underpinnings of verbal fluency impairment after chronic subthalamic stimulation in Parkinson's disease. (2006) (90)
- The burden of non-motor symptoms in Parkinson's disease using a self-completed non-motor questionnaire: a simple grading system. (2015) (88)
- Apomorphine and levodopa infusion therapies for advanced Parkinson’s disease: selection criteria and patient management (2009) (88)
- Excessive daytime sleepiness in multiple system atrophy (SLEEMSA study). (2011) (88)
- Behavioural Adverse Effects of Dopaminergic Treatments in Parkinson’s Disease (2009) (87)
- Management of Advanced Therapies in Parkinson's Disease Patients in Times of Humanitarian Crisis: The COVID‐19 Experience (2020) (86)
- Tc‐99m ethylene cysteinate dimer SPECT in the differential diagnosis of parkinsonism (2002) (85)
- A Consensus Set of Outcomes for Parkinson’s Disease from the International Consortium for Health Outcomes Measurement (2017) (85)
- Psychosis associated to Parkinson's disease in the early stages: relevance of cognitive decline and depression (2011) (85)
- Prevalence and features of peripheral neuropathy in Parkinson's disease patients under different therapeutic regimens. (2014) (83)
- COVID-19 and possible links with Parkinson’s disease and parkinsonism: from bench to bedside (2020) (83)
- Management of impulse control disorders in Parkinson's disease: Controversies and future approaches (2015) (83)
- Non-motor outcomes depend on location of neurostimulation in Parkinson's disease. (2019) (82)
- Non-motor outcomes depend on location of neurostimulation in Parkinson's disease. (2019) (82)
- Beneficial Effects of Bilateral Subthalamic Stimulation on Non-Motor Symptoms in Parkinson's Disease (2016) (81)
- Dopamine D2 Receptors in Normal Human Brain: Effect of Age Measured by Positron Emission Tomography (PET) and [11C]‐Raclopride a (1993) (81)
- How many parkinsonian patients are suitable candidates for deep brain stimulation of subthalamic nucleus? Results of a questionnaire. (2007) (81)
- Imaging essential tremor (2010) (80)
- Preoperative and postoperative glucose consumption in mesiobasal and lateral temporal lobe epilepsy (1994) (80)
- The status of dopamine nerve terminals in Parkinson's disease and essential tremor: a PET study with the tracer [11-C]FE-CIT (2001) (80)
- The reliability of a deep learning model in clinical out-of-distribution MRI data: a multicohort study (2019) (78)
- Dopamine Transporter SPECT Imaging in Corticobasal Syndrome (2011) (78)
- Effect of levodopa‐carbidopa intestinal gel on dyskinesia in advanced Parkinson's disease patients (2016) (78)
- PINK1 heterozygous rare variants: prevalence, significance and phenotypic spectrum (2008) (77)
- Cognitive profiling of Parkinson disease patients with mild cognitive impairment and dementia. (2014) (77)
- Surgical, medical, and hardware adverse events in a series of 141 patients undergoing subthalamic deep brain stimulation for Parkinson disease. (2010) (76)
- Patterns of cortical thickness associated with impulse control disorders in Parkinson's disease (2015) (76)
- Axonal damage and loss of connectivity in nigrostriatal and mesolimbic dopamine pathways in early Parkinson's disease (2017) (75)
- Novel formulations and modes of delivery of levodopa (2015) (75)
- The role of high‐field magnetic resonance imaging in parkinsonian disorders: Pushing the boundaries forward (2017) (74)
- A randomized clinical trial to evaluate the effects of rasagiline on depressive symptoms in non-demented Parkinson’s disease patients (2015) (74)
- Cerebral glucose metabolism in patients with spasmodic torticollis (1997) (74)
- Brain networks underlining verbal fluency decline during STN-DBS in Parkinson's disease: an ECD-SPECT study. (2007) (73)
- Hydrocarbon exposure and Parkinson’s disease (2000) (73)
- Radiosynthesis of [18F] N-3-fluoropropyl-2-β-carbomethoxy-3-β-(4-iodophenyl) nortropane and the first human study with positron emission tomography (1996) (72)
- Characterizing motor and non-motor aspects of early-morning off periods in Parkinson's disease: an international multicenter study. (2014) (72)
- Prevalence and associated features of self-reported freezing of gait in Parkinson disease: The DEEP FOG study. (2015) (72)
- How to apply the movement disorder society criteria for diagnosis of progressive supranuclear palsy (2019) (71)
- A cross-sectional multicenter study of cognitive and behavioural features in multiple system atrophy patients of the parkinsonian and cerebellar type (2013) (71)
- Novel parkin mutations detected in patients with early‐onset Parkinson's disease (2005) (70)
- Perfusion ECD/SPECT in the characterization of cognitive deficits in Parkinson's disease (2001) (70)
- Grey Matter Changes in Cognitively Impaired Parkinson's Disease Patients (2014) (69)
- Whole gene deletion and splicing mutations expand the PINK1 genotypic spectrum (2007) (69)
- A European multicentre survey of impulse control behaviours in Parkinson's disease patients treated with short‐ and long‐acting dopamine agonists (2016) (68)
- Nonmotor symptoms evolution during 24 months of bilateral subthalamic stimulation in Parkinson's disease (2018) (68)
- Brain volume changes in Parkinson's disease and their relationship with cognitive and behavioural abnormalities (2011) (65)
- Striatal dopamine transporter abnormalities in patients with essential tremor (2008) (65)
- Pros and cons of apomorphine and L-dopa continuous infusion in advanced Parkinson's disease. (2009) (64)
- Oral and Infusion Levodopa-Based Strategies for Managing Motor Complications in Patients with Parkinson’s Disease (2010) (64)
- Role of genetic polymorphisms of the dopaminergic system in Parkinson's disease patients with impulse control disorders. (2012) (64)
- Viewpoint and practical recommendations from a movement disorder specialist panel on objective measurement in the clinical management of Parkinson’s disease (2018) (64)
- Effects of rotigotine transdermal patch in patients with Parkinson's disease presenting with non‐motor symptoms – results of a double‐blind, randomized, placebo‐controlled trial (2015) (64)
- Cognitive and MRI correlates of orthostatic hypotension in Parkinson’s disease (2012) (63)
- Magnetic Resonance Parkinsonism Index: diagnostic accuracy of a fully automated algorithm in comparison with the manual measurement in a large Italian multicentre study in patients with progressive supranuclear palsy (2017) (63)
- USP14 inhibition corrects an in vivo model of impaired mitophagy (2018) (63)
- Default mode network links to visual hallucinations: A comparison between Parkinson's disease and multiple system atrophy (2015) (62)
- [123I]FP-CIT striatal binding in early Parkinson's disease patients with tremor vs. akinetic-rigid onset (2007) (61)
- Effect and safety of duodenal levodopa infusion in advanced Parkinson’s disease: a retrospective multicenter outcome assessment in patient routine care (2013) (60)
- Clinical and [123I]FP-CIT SPET imaging follow-up in patients with drug-induced parkinsonism (2009) (60)
- Continuous apomorphine infusion (CAI) and neuropsychiatric disorders in patients with advanced Parkinson's disease: a follow-up of two years. (2004) (60)
- A critique of the second consensus criteria for multiple system atrophy (2019) (59)
- Impulse control disorders in advanced Parkinson's disease with dyskinesia: The ALTHEA study (2017) (59)
- Preoperative indicators of clinical outcome following stereotaxic pallidotomy (1997) (59)
- Do patients with late-stage Parkinson's disease still respond to levodopa? (2016) (57)
- The relationship between cerebral vascular disease and parkinsonism: The VADO study. (2012) (56)
- Cost‐effectiveness of 123I‐FP‐CIT SPECT in the differential diagnosis of essential tremor and Parkinson's disease in Italy (2008) (56)
- Intrajejunal Levodopa Versus Conventional Therapy in Parkinson Disease: Motor and Nonmotor Effects (2012) (55)
- Loss of thalamic serotonin transporters in early drug-naïve Parkinson’s disease patients is associated with tremor: an [123I]β-CIT SPECT study (2008) (54)
- Pain in Parkinson's disease: facts and uncertainties (2018) (54)
- Montreal Cognitive Assessment (MoCA) and Mini-Mental State Examination (MMSE) performance in progressive supranuclear palsy and multiple system atrophy (2016) (54)
- Cognitive status of patients with Parkinson’s disease and pathological gambling (2010) (54)
- Peripheral nervous system involvement in Parkinson's disease: evidence and controversies. (2014) (54)
- PD_Manager: an mHealth platform for Parkinson's disease patient management (2017) (53)
- COMT inhibition with tolcapone in the treatment algorithm of patients with Parkinson’s disease (PD): relevance for motor and non-motor features (2008) (53)
- Anatomical and functional correlates of persistent pain in Parkinson's disease (2016) (53)
- Disease progression in Parkinson subtypes: the PPMI dataset (2018) (53)
- Hyperhomocysteinemia in levodopa‐treated patients with Parkinson's disease dementia (2009) (53)
- Benzodiazepine receptor binding in Huntington's disease: [11C]Flumazenil uptake measured using positron emission tomography (2000) (53)
- Parkin analysis in early onset Parkinson's disease. (2008) (53)
- Double-blind Randomized Trial of t-DCS Versus Sham in Parkinson Patients With Mild Cognitive Impairment Receiving Cognitive Training (2015) (52)
- Anatomical Correlates of Cognitive Functions in Early Parkinson's Disease Patients (2013) (51)
- Clinical and cerebral activity changes induced by subthalamic nucleus stimulation in advanced Parkinson's disease: A prospective case-control study (2009) (51)
- A signature pattern of cortical atrophy in dementia with Lewy bodies: A study on 333 patients from the European DLB consortium (2018) (50)
- Brain SPECT imaging in multiple system atrophy (2005) (50)
- Impulse control disorder related behaviours during long‐term rotigotine treatment: a post hoc analysis (2016) (49)
- Increased striatal glucose consumption in sydenham's chorea (1993) (49)
- Extradural motor cortex stimulation in Parkinson's disease (2007) (49)
- Speech and Voice Response to a Levodopa Challenge in Late-Stage Parkinson’s Disease (2017) (49)
- Increased cerebral iron uptake in Wilson's disease: a 52Fe-citrate PET study. (2000) (49)
- Diagnostic and screening power of neuropsychological testing in detecting mild cognitive impairment in Parkinson’s disease (2013) (49)
- Anhedonia and cognitive impairment in Parkinson's disease: Italian validation of the Snaith-Hamilton Pleasure Scale and its application in the clinical routine practice during the PRIAMO study. (2009) (48)
- The “Gender Factor” in Wearing-Off among Patients with Parkinson's Disease: A Post Hoc Analysis of DEEP Study (2015) (47)
- Thin Section MR Study of the Basal Ganglia in the Differential Diagnosis Between Striatonigral Degeneration and Parkinson Disease (2002) (46)
- An overnight switch to ropinirole therapy in patients with Parkinson's disease (1999) (46)
- Pisa syndrome without neuroleptic exposure in a patient with Parkinson's disease: Case report (2006) (46)
- Autosomal recessive early onset parkinsonism is linked to three loci: PARK2, PARK6, and PARK7 (2002) (46)
- Which patients discontinue? Issues on Levodopa/carbidopa intestinal gel treatment: Italian multicentre survey of 905 patients with long-term follow-up. (2017) (45)
- Non-motor outcomes of subthalamic stimulation in Parkinson's disease depend on location of active contacts (2018) (45)
- Nutritional habits, risk, and progression of Parkinson disease (2017) (44)
- Caregiver burden and its related factors in advanced Parkinson’s disease: data from the PREDICT study (2018) (44)
- Brain structural profile of multiple system atrophy patients with cognitive impairment (2017) (44)
- Therapeutic strategies to prevent and manage dyskinesias in Parkinson’s disease (2015) (44)
- Neuropathology of Parkinson's disease associated with the LRRK2 Ile1371Val mutation (2007) (44)
- Epilepsia partialis continua studied by PET (1991) (43)
- Continuous dopaminergic stimulation--from theory to clinical practice. (2007) (43)
- Comparative analysis of visual and semi-quantitative assessment of striatal [123I]FP-CIT-SPET binding in Parkinson's disease (2006) (43)
- Role of Pramipexole in the Management of Parkinson’s Disease (2010) (43)
- Targeting of the Subthalamic Nucleus for Deep Brain Stimulation: A Survey Among Parkinson Disease Specialists. (2017) (42)
- [123I]FP‐CIT SPET imaging in drug‐induced Parkinsonism (2008) (42)
- Anatomical identification of active contacts in subthalamic deep brain stimulation. (2007) (41)
- The contribution of white matter lesions to Parkinson’s disease motor and gait symptoms: a critical review of the literature (2016) (41)
- Striatal dopamine transporter binding in Parkinson's disease associated with the LRRK2 Gly2019Ser mutation (2006) (41)
- Temporal lobe epilepsy: Correlation of proton magnetic resonance spectroscopy and 18F‐fluorodeoxyglucose positron emission tomography (1997) (41)
- Increased oxidative stress in lymphocytes from untreated Parkinson's disease patients. (2009) (40)
- Quality of life outcome after subthalamic stimulation in Parkinson's disease depends on age (2018) (40)
- Response of non-motor symptoms to levodopa in late-stage Parkinson's disease: Results of a levodopa challenge test. (2017) (39)
- Substantia Nigra Neuromelanin as an Imaging Biomarker of Disease Progression in Parkinson's Disease. (2017) (39)
- Predictive value of nigrostriatal dysfunction in isolated tremor: A clinical and SPECT study (2008) (39)
- alpha-Synuclein multiplication analysis in Italian familial Parkinson disease. (2010) (39)
- Should there be less emphasis on levodopa‐induced dyskinesia in Parkinson's disease? (2019) (39)
- PET and SPECT functional imaging in Parkinson's disease. (2004) (39)
- Continuous intestinal infusion of levodopa/carbidopa in advanced Parkinson's disease: efficacy, safety and patient selection. (2012) (38)
- Parkinson's Disease and Post–COVID‐19 Syndrome: The Parkinson's Long‐COVID Spectrum (2021) (38)
- The status of olfactory function and the striatal dopaminergic system in drug-induced parkinsonism (2010) (38)
- Comparison of 123I‐IBZM SPECT and 11C‐raclopride PET findings in patients with parkinsonism (1994) (38)
- Continuous apomorphine infusion and neuropsychiatric disorders: a controlled study in patients with advanced Parkinson’s disease (2003) (37)
- Psychiatric symptoms in Parkinson’s disease assessed with the SCL-90R self-reported questionnaire (2010) (37)
- Secondary Parkinsonism due to focal substantia nigra lesions: a PET study with [18F]FDG and [18F]Fluorodopa (1996) (36)
- Stridor in multiple system atrophy (2019) (36)
- Cognitive Rehabilitation in Parkinson's Disease: Is it Feasible? (2017) (35)
- Reasons for hospitalization in Parkinson's disease: a case-control study. (2014) (35)
- Switching from constant voltage to constant current in deep brain stimulation: a multicenter experience of mixed implants for movement disorders (2016) (35)
- Motor and non-motor outcomes in patients with advanced Parkinson’s disease treated with levodopa/carbidopa intestinal gel: final results of the GREENFIELD observational study (2019) (35)
- Genetic, clinical, and imaging characterization of one patient with late‐onset, slowly progressive, pantothenate kinase‐associated neurodegeneration (2006) (34)
- Pramipexole‐treated Parkinson's disease during pregnancy (2004) (34)
- The efficacy of oral adenosine A2A antagonist istradefylline for the treatment of moderate to severe Parkinson’s disease (2015) (34)
- Spinal Cord Stimulation for the Treatment of Sensory Symptoms in Advanced Parkinson's Disease (2013) (34)
- Short-term quality of life after subthalamic stimulation depends on non-motor symptoms in Parkinson's disease (2018) (33)
- Differential neuropsychological profiles in Parkinsonian patients with or without vascular lesions (2010) (33)
- Adherence to anti-Parkinson drug therapy in the “REASON” sample of Italian patients with Parkinson’s disease: the linguistic validation of the Italian version of the “Morisky Medical Adherence scale-8 items” (2013) (32)
- D2 receptor binding in dopa‐responsive dystonia (1998) (32)
- The PRIAMO study: urinary dysfunction as a marker of disease progression in early Parkinson's disease (2017) (32)
- Brain Amyloid Contribution to Cognitive Dysfunction in Early-Stage Parkinson's Disease: The PPMI Dataset. (2018) (31)
- The PRIAMO study: background, methods and recruitment (2008) (31)
- Deep brain stimulation and its effect on sleep in Parkinson's disease. (2004) (31)
- Distribution and impact on quality of life of the pain modalities assessed by the King’s Parkinson’s disease pain scale (2017) (31)
- Dopa‐responsive pseudo‐orthostatic tremor in parkinsonism (2007) (31)
- Water-based vs. non-water-based physiotherapy for rehabilitation of postural deformities in Parkinson’s disease: a randomized controlled pilot study (2017) (31)
- The Non‐Motor Symptoms Scale in Parkinson’s disease: Validation and use (2020) (31)
- Dopamine transporter imaging study in parkinsonism occurring in fragile X premutation carriers (2005) (30)
- Cerebral autoregulation and white matter lesions in Parkinson's disease and multiple system atrophy. (2015) (30)
- Deep brain stimulation for the treatment of Parkinson's disease: the experience of the Neurosurgical Department in Monza (2003) (30)
- Relevance of sleep quality on caregiver burden in Parkinson’s disease (2018) (30)
- Striatal dopamine D2 receptors in patients with narcolepsy measured with PET and 11C‐raclopride (1994) (30)
- Evidence of delayed nigrostriatal dysfunction in corticobasal syndrome: a SPECT follow-up study. (2013) (30)
- Functional motor disorders associated with other neurological diseases: Beyond the boundaries of “organic” neurology (2020) (30)
- Clinical Correlates of Functional Motor Disorders: An Italian Multicenter Study (2020) (29)
- Continuous dopaminergic stimulation achieved by duodenal levodopa infusion (2008) (29)
- Automated MRI Classification in Progressive Supranuclear Palsy: A Large International Cohort Study (2020) (29)
- n‐Hexane‐induced parkinsonism: Pathogenetic hypotheses (1995) (29)
- Relationship between pain and motor and non‐motor symptoms in Parkinson's disease (2017) (28)
- Biological effects of the PINK1 c.1366C>T mutation: implications in Parkinson disease pathogenesis (2007) (28)
- Apathy in Mild Parkinson's Disease: Neuropsychological and Neuroimaging Evidence. (2016) (28)
- Deep brain stimulation for monogenic Parkinson’s disease: a systematic review (2019) (28)
- Therapy-resistant symptoms in Parkinson’s disease (2015) (27)
- Treatment with D‐penicillamine improves dopamine D2‐receptor binding and T2‐signal intensity in de novo Wilson's disease (1994) (27)
- COVID-19 and possible links with Parkinson’s disease and parkinsonism: from bench to bedside (2020) (27)
- Device-Aided Treatment Strategies in Advanced Parkinson's Disease. (2017) (27)
- Diagnosing dementia in multiple system atrophy by applying Movement Disorder Society diagnostic criteria for Parkinson's disease dementia. (2015) (27)
- Neuroimaging biomarkers for clinical trials in atypical parkinsonian disorders: Proposal for a Neuroimaging Biomarker Utility System (2019) (26)
- Anatomy and Connectivity of the Subthalamic Nucleus in Humans and Non-human Primates (2020) (26)
- Improvement of dyskinesias with l‐dopa infusion in advanced Parkinson's disease (2016) (26)
- Heart rate circadian profile in the differential diagnosis between Parkinson disease and multiple system atrophy. (2014) (25)
- Cognitive impairment in multiple system atrophy (2017) (25)
- Motor outcomes in patients with advanced Parkinson’s disease treated with levodopa/carbidopa intestinal gel in Italy: an interim analysis from the GREENFIELD observational study (2016) (25)
- Diagnosis of possible mild cognitive impairment in Parkinson's disease: validity of the SCOPA-Cog. (2013) (25)
- Levodopa-Carbidopa Intestinal Gel Monotherapy: GLORIA Registry Demographics, Efficacy, and Safety (2019) (25)
- Subthalamic Stimulation Improves Quality of Life of Patients Aged 61 Years or Older With Short Duration of Parkinson's Disease (2018) (25)
- [On-off phenomena in Parkinson's disease. Continuous dopaminergic stimulation]. (1987) (25)
- A prospective, controlled study of non-motor effects of subthalamic stimulation in Parkinson’s disease: results at the 36-month follow-up (2020) (25)
- Apomorphine and levodopa infusion for motor fluctuations and dyskinesia in advanced Parkinson disease (2018) (24)
- 123 I-Ioflupane / SPECT binding to striatal dopamine transporter ( DAT ) uptake in patients with Parkinson ’ s disease , multiple system atrophy , and progressive supranuclear palsy (2003) (24)
- Novel levodopa formulations in the treatment of Parkinson's disease (2014) (24)
- Levodopa and 3-OMD levels in Parkinson patients treated with Duodopa (2010) (24)
- Successful subthalamic stimulation in genetic Parkinson’s disease caused by duplication of the α-synuclein gene (2011) (24)
- Levodopa–carbidopa intrajejunal gel in advanced Parkinson disease with “on” freezing of gait (2015) (24)
- A voxel-based PET study of dopamine transporters in Parkinson's disease: Relevance of age at onset (2008) (24)
- The feasibility of statistical parametric mapping for the analysis of positron emission tomography studies using 11C-2-β-carbomethoxy-3-β-(4-fluorophenyl)-tropane in patients with movement disorders (2002) (24)
- Regression of cardiac valvulopathy related to ergot-derived dopamine agonists. (2011) (23)
- Application of the '5-2-1' screening criteria in advanced Parkinson's disease: interim analysis of DUOGLOBE. (2020) (23)
- Foot Pressure Wearable Sensors for Freezing of Gait Detection in Parkinson’s Disease (2020) (23)
- Multiple system atrophy as emerging template for accelerated drug discovery in α-synucleinopathies (2014) (22)
- Can therapeutic strategies prevent and manage dyskinesia in Parkinson’s disease? An update (2019) (22)
- Dopamine agonist-based strategies in the treatment of Parkinson’s disease (2008) (22)
- Striatal dopaminergic denervation in early and late onset Parkinson's disease assessed by PET and the tracer [11C]FECIT: preliminary findings in one patient with autosomal recessive parkinsonism (Park2) (2002) (22)
- The Long-Term Impact of Levodopa/Carbidopa Intestinal Gel on ‘Off’-time in Patients with Advanced Parkinson’s Disease: A Systematic Review (2021) (22)
- Positron emission tomography in drug evaluation: influence of three different catechol-O-methyltransferase inhibitors on metabolism of [NCA] 6-[18F]fluoro-L-dopa in rhesus monkey. (1995) (22)
- Linguistic, psychometric validation and diagnostic ability assessment of an Italian version of a 19-item wearing-off questionnaire for wearing-off detection in Parkinson’s disease (2012) (22)
- Pharmacological and PET studies in patient’s with Parkinson’s disease and a short duration-motor response: implications in the pathophysiology of motor complications (2004) (22)
- Cohort study of prevalence and phenomenology of tremor in dementia with Lewy bodies (2013) (21)
- Pharmacokinetic evaluation of pramipexole (2011) (21)
- Cerebral activity modulation by extradural motor cortex stimulation in Parkinson's disease: a perfusion SPECT study (2007) (21)
- Understanding and Treating Pain Syndromes in Parkinson's Disease. (2017) (21)
- Stridor in multiple system atrophy Consensus statement on diagnosis, prognosis, and treatment (2019) (21)
- Characteristics and progression of cognitive deficits in progressive supranuclear palsy vs. multiple system atrophy and Parkinson’s disease (2019) (21)
- Parkinson's disease, chronic hydrocarbon exposure and striatal neuronal damage: a 1-H MRS study. (2006) (21)
- Overground robot assisted gait trainer for the treatment of drug-resistant freezing of gait in Parkinson disease (2015) (21)
- Monitoring of motor and non-motor symptoms of Parkinson's disease through a mHealth platform (2016) (21)
- An Observational Study of the Effect of Levodopa–Carbidopa Intestinal Gel on Activities of Daily Living and Quality of Life in Advanced Parkinson’s Disease Patients (2017) (21)
- Dysphagia predicts poor outcome in late-stage Parkinson's disease. (2019) (20)
- The Possible Clinical Predictors of Fatigue in Parkinson's Disease: A Study of 135 Patients as Part of International Nonmotor Scale Validation Project (2011) (20)
- Beneficial nonmotor effects of subthalamic and pallidal neurostimulation in Parkinson’s disease (2020) (20)
- Technology-Enabled Care: Integrating Multidisciplinary Care in Parkinson's Disease Through Digital Technology (2020) (20)
- Single-Photon Emission Computed Tomography in Diagnosis and Differential Diagnosis of Parkinson’s Disease (2010) (20)
- Dopamine Receptors in Parkinson's Disease: A Meta‐Analysis of Imaging Studies (2021) (20)
- The End Is the Beginning: Parkinson’s Disease in the Light of Brain Imaging (2017) (20)
- Validation of the Italian version of Parkinson’s Disease-Cognitive Rating Scale (PD-CRS) (2014) (20)
- European Academy of Neurology/Movement Disorder Society‐European Section Guideline on the Treatment of Parkinson's Disease: I. Invasive Therapies (2022) (19)
- Multifocal alterations of white matter accompany the transition from normal cognition to dementia in Parkinson’s disease patients (2019) (19)
- A New MRI Measure to Early Differentiate Progressive Supranuclear Palsy From De Novo Parkinson's Disease in Clinical Practice: An International Study (2020) (19)
- Arterial hypertension, a tricky side of Parkinson’s disease: physiopathology and therapeutic features (2013) (19)
- Pulsatile or continuous dopaminomimetic strategies in Parkinson's disease. (2012) (19)
- Continuous dopaminergic delivery in Parkinson’s disease (2010) (18)
- Brain flow changes before and after deep brain stimulation of the subthalamic nucleus in Parkinson’s disease (2003) (18)
- Observational study of sleep-related disorders in Italian patients with Parkinson’s disease: usefulness of the Italian version of Parkinson’s disease sleep scale (2012) (18)
- Clinical utility of DaTscan in patients with suspected Parkinsonian syndrome: a systematic review and meta-analysis (2021) (18)
- Modification of dopamine D2 receptor activity by pergolide in Parkinson's disease: an in vivo study by PET. (1999) (18)
- Long-term effect of subthalamic and pallidal deep brain stimulation for status dystonicus in children with methylmalonic acidemia and GNAO1 mutation (2019) (18)
- Subcutaneous lisuride infusion in Parkinson's disease: clinical results using different modes of administration. (1988) (18)
- P1.229 Improvement of motor and non-motor symptoms after switching from oral therapy to continuous duodenal levodopa infusion in advanced Parkinson's disease (2009) (18)
- Reasons driving treatment modification in Parkinson's disease: results from the cross-sectional phase of the REASON study. (2013) (18)
- Beneficial effect of 24-month bilateral subthalamic stimulation on quality of sleep in Parkinson’s disease (2020) (17)
- Moving towards home-based community-centred integrated care in Parkinson's disease. (2020) (17)
- Acceptability to patients, carers and clinicians of an mHealth platform for the management of Parkinson’s disease (PD_Manager): study protocol for a pilot randomised controlled trial (2018) (17)
- Levodopa–carbidopa intestinal gel in a subgroup of patients with dyskinesia at baseline from the GLORIA Registry (2018) (17)
- What is the best treatment for fluctuating Parkinson’s disease: continuous drug delivery or deep brain stimulation of the subthalamic nucleus? (2011) (17)
- Beneficial effect of 24-month bilateral subthalamic stimulation on quality of sleep in Parkinson’s disease (2020) (17)
- Nigral anatomy and striatal denervation in genetic Parkinsonism: A family report (2015) (17)
- Burden of non‐motor symptoms in Parkinson's disease patients predicts improvement in quality of life during treatment with levodopa‐carbidopa intestinal gel (2018) (17)
- Idiopathic delayed-onset edema surrounding deep brain stimulation leads: Insights from a case series and systematic literature review. (2016) (17)
- Non-motor predictors of 36-month quality of life after subthalamic stimulation in Parkinson disease (2021) (16)
- Validation and attempts of revision of the MDS-recommended tests for the screening of Parkinson's disease dementia. (2014) (16)
- Functional neuroimaging (PET and SPECT) in the selection and assessment of patients with Parkinson's disease undergoing deep brain stimulation. (2003) (16)
- Targeting pain in Parkinson's disease (2015) (16)
- A decision support system for Parkinson disease management: expert models for suggesting medication change (2018) (16)
- Frontal and subcortical contribution to visual hallucinations in dementia with Lewy bodies and Parkinson’s disease (2019) (15)
- Validation of a home environment test battery for supporting assessments in advanced Parkinson’s disease (2012) (15)
- Frontal assessment battery scores and non-motor symptoms in parkinsonian disorders (2012) (15)
- Personalised Advanced Therapies in Parkinson’s Disease: The Role of Non-Motor Symptoms Profile (2021) (15)
- The Neural Correlates of Spatial and Object Working Memory in Elderly and Parkinson's Disease Subjects (2015) (15)
- Handbook of Non-Motor Symptoms in Parkinson's Disease (2012) (15)
- Clinical Experiences With Levodopa Methylester (Melevodopa) in Patients With Parkinson Disease Experiencing Motor Fluctuations: An Open-Label Observational Study (2010) (15)
- Adenosine A2A receptor antagonists in Parkinson's disease: still in the running (2014) (15)
- Once-daily pramipexole for the treatment of early and advanced idiopathic Parkinson’s disease: implications for patients (2011) (15)
- Acute response of non-motor symptoms to subthalamic deep brain stimulation in Parkinson's disease. (2017) (15)
- New strategies in motor parkinsonism. (2007) (14)
- Consensus on the treatment of dysphagia in Parkinson's disease (2021) (14)
- Subthalamic Stimulation Improves Quality of Sleep in Parkinson Disease: A 36-Month Controlled Study. (2020) (14)
- Parkinson disease: Can dopamine transporter imaging define early PD? (2014) (14)
- First comprehensive tool for screening pain in Parkinson's disease: the King's Parkinson's Disease Pain Questionnaire (2018) (14)
- The rationale for improved integration between home care and neurology hospital services in patients with advanced Parkinson’s disease (2008) (14)
- Age/disease duration influence on activities of daily living and quality of life after levodopa-carbidopa intestinal gel in Parkinson's disease. (2018) (14)
- The PRIAMO study: age- and sex-related relationship between prodromal constipation and disease phenotype in early Parkinson’s disease (2020) (14)
- Impact of social and mobility restrictions in Parkinson’s disease during COVID-19 lockdown (2021) (14)
- Apomorphine and Levodopa Infusion Therapies for Advanced Parkinson’s Disease (2009) (14)
- Cerebral 6-[18F]fluoro-l-DOPA uptake in rhesus monkey: pharmacological influence of aromatic amino acid decarboxylase (AAAD) and catechol-O-methyltransferase (COMT) inhibition (1997) (14)
- Long-term intracerebral infusion of fibroblast growth factors restores motility and enhances F-DOPA uptake in parkinsonian monkeys. (1998) (14)
- Tremor UPDRS estimation in home environment (2016) (14)
- Feasibility and Utility of mHealth for the Remote Monitoring of Parkinson Disease: Ancillary Study of the PD_manager Randomized Controlled Trial (2020) (14)
- The PRIAMO study: age- and sex-related relationship between prodromal constipation and disease phenotype in early Parkinson’s disease (2020) (14)
- Immunization therapies for Parkinson’s disease: state of the art and considerations for future clinical trials (2020) (13)
- The effect of repeated administrations of granulocyte colony stimulating factor for blood stem cells mobilization in patients with progressive supranuclear palsy, corticobasal degeneration and multiple system atrophy (2010) (13)
- The PRIAMO study: active sexual life is associated with better motor and non‐motor outcomes in men with early Parkinson's disease (2019) (13)
- “Gunslinger’s gait”: a new cause of unilaterally reduced arm swing (2015) (13)
- Erratum: A proposal for a comprehensive grading of Parkinson's disease severity combining motor and non-motor assessments: Meeting an unmet need (PLoS ONE (2013) 8: 2 (e57221) DOI: 10.1371/journal.pone.0057221) (2016) (13)
- [123I]FP-CIT SPECT findings in two patients with Hallervorden–Spatz disease with homozygous mutation in PANK2 gene (2005) (13)
- Blood to brain iron uptake in one rhesus monkey using [Fe-52]-citrate and positron emission tomography (PET): influence of haloperidol. (1994) (13)
- Asymmetric Dopamine Transporter Loss Affects Cognitive and Motor Progression in Parkinson's Disease (2021) (13)
- Differences in cognitive profiles between Lewy body and Parkinson’s disease dementia (2020) (13)
- Striatal Dopamine D2 Receptors in Dopa-Responsive Dystonia and Parkinson’s Disease (1995) (13)
- Relationship of Nocturnal Sleep Dysfunction and Pain Subtypes in Parkinson's Disease (2018) (13)
- Clinical and imaging characterization of a patient with idiopathic progressive ataxia and palatal tremor (2007) (12)
- Moving towards Integrated and Personalized Care in Parkinson’s Disease: A Framework Proposal for Training Parkinson Nurses (2021) (12)
- A Pilot Prospective, Multicenter Observational Study of Dopamine Agonist Withdrawal Syndrome in Parkinson's Disease (2015) (12)
- Dysphagia in multiple system atrophy consensus statement on diagnosis, prognosis and treatment. (2021) (12)
- Impairment of human dopaminergic neurons at different developmental stages by perfluoro-octanoic acid (PFOA) and differential human brain areas accumulation of perfluoroalkyl chemicals. (2021) (12)
- Can suitable candidates for levodopa/carbidopa intestinal gel therapy be identified using current evidence? (2017) (12)
- Nonmotor Symptoms and Natural History of Parkinson's Disease: Evidence From Cognitive Dysfunction and Role of Noninvasive Interventions. (2017) (12)
- Safety of Levodopa-Carbidopa Intestinal Gel Treatment in Patients with Advanced Parkinson's Disease Receiving ≥2000 mg Daily Dose of Levodopa (2020) (12)
- Dopamine agonists early monotherapy for the delay of development of levodopa-induced dyskinesias (2015) (12)
- Comparison of self‐reported symptoms and psychophysical tests in coronavirus disease 2019 (COVID‐19) subjects experiencing long‐term olfactory dysfunction: a 6‐month follow‐up study (2021) (12)
- Rotigotine transdermal patch in the management of Parkinson's disease (PD) and its night-time use for PD-related sleep disorders. (2010) (11)
- The role of I-ioflupane SPECT dopamine transporter imaging in the diagnosis and treatment of patients with dementia with Lewy bodies. (2007) (11)
- Sleep in Genetically Confirmed Pantothenate Kinase-Associated Neurodegeneration: A Video-Polysomnographic Study (2010) (11)
- mHealth Platform for Parkinson’s Disease Management (2015) (11)
- Radiosynthesis of [11C]brofaromine, a potential tracer for imaging monoamine oxidase A. (1996) (11)
- Unraveling depression in Parkinson’s disease (2008) (11)
- European Academy of Neurology/Movement Disorder Society ‐ European Section guideline on the treatment of Parkinson's disease: I. Invasive therapies (2022) (11)
- A multinational consensus on dysphagia in Parkinson's disease: screening, diagnosis and prognostic value (2021) (11)
- The impact of COVID-19 on palliative care for people with Parkinson’s and response to future pandemics (2021) (11)
- Effects of terguride in patients with Huntington's disease. (1989) (10)
- Validation and clinical value of the MANAGE-PD tool: A clinician-reported tool to identify Parkinson's disease patients inadequately controlled on oral medications. (2021) (10)
- Globus pallidus internus deep brain stimulation for the treatment of status dystonicus in tardive dystonia (2016) (10)
- Digital health technology for non-motor symptoms in people with Parkinson's disease: Futile or future? (2021) (10)
- MRI indirect stereotactic targeting for deep brain stimulation in Parkinson's disease. (2003) (10)
- Cerebral metabolic changes (18F-FDG PET) during selective anterior temporal lobe amobarbital test. (1997) (10)
- Dopaminergic Medication Modulates Learning from Feedback and Error-Related Negativity in Parkinson’s Disease: A Pilot Study (2016) (10)
- Imaging for early differential diagnosis of parkinsonism (2010) (10)
- Dopaminergic treatment and nonmotor features of Parkinson disease (2013) (10)
- Imaging evidence supports a link between essential tremor and Parkinson's disease. (2009) (10)
- Validity and metric of MiniMental Parkinson and MiniMental State Examination in Parkinson’s disease (2013) (10)
- Striatal dopamine transporter binding in patients with Parkinson's disease and severe occupational hydrocarbon exposure (2007) (9)
- [Cost analysis in Italy of various strategies for the treatment of Parkinson disease in the advanced phase]. (2003) (9)
- Apomorphine infusion in advanced Parkinson disease (2018) (9)
- Access and Attitudes Toward Palliative Care Among Movement Disorders Clinicians (2021) (9)
- The MTHFR C677T polymorphism modifies age at onset in Parkinson’s disease (2013) (9)
- Mhealth for remote monitoring and management of Parkinson’s disease: determinants of compliance and validation of a tremor evaluation method (2020) (8)
- Predicting rapid progression of Parkinson's Disease at baseline patients evaluation (2017) (8)
- Patients with rest-tremor and scans with ipsilateral dopaminergic deficit (2013) (8)
- European multicentre survey of tolerability rates and impulse control behaviour trends of prolonged release dopamine agonists in young and old PD (2012) (7)
- Is there room for new non-dopaminergic treatments in Parkinson’s disease? (2013) (7)
- Pathological gambling in Parkinson’s disease: disease related or drug related? (2011) (7)
- Clinical variables associated with treatment changes in Parkinson’s disease: results from the longitudinal phase of the REASON study (2015) (7)
- Development and Validation of Automated Magnetic Resonance Parkinsonism Index 2.0 to Distinguish Progressive Supranuclear Palsy‐Parkinsonism From Parkinson's Disease (2022) (7)
- The Added Benefit of Opicapone When Used Early in Parkinson's Disease Patients With Levodopa-Induced Motor Fluctuations: A Post-hoc Analysis of BIPARK-I and -II (2021) (7)
- The TANDEM investigation: efficacy and tolerability of levodopa-carbidopa intestinal gel in (LCIG) advanced Parkinson’s disease patients (2020) (7)
- Cortical visual evoked potentials recorded after optic tract near field stimulation during GPi-DBS in non-cooperative patients (2011) (7)
- Effects of rotigotine on Parkinson's disease-related sleep disturbances (2013) (7)
- Impact of Cognitive Profile on Impulse Control Disorders Presence and Severity in Parkinson's Disease (2019) (7)
- Side effects of the catechol-O-methyl-transferase inhibitor Ro 40-7592 in rabbits. (1994) (6)
- Education on palliative care for Parkinson patients: development of the “Best care for people with late-stage Parkinson’s disease” curriculum toolkit (2021) (6)
- Radiosynthesis of [18F] N-3-fluoropropyl-2-beta-carbomethoxy-3-beta-(4-iodophenyl) nortropane and the first human study with positron emission tomography. (1996) (6)
- Tolerability of non-ergot oral and transdermal dopamine agonists in younger and older Parkinson’s disease patients: an European multicentre survey (2020) (6)
- Prevalence of Extrapyramidal Symptoms in In-Patients With Severe Mental Illnesses: Focus on Parkinsonism (2020) (6)
- Deep brain stimulation in Parkinson's disease: A multicentric, long-term, observational pilot study (2019) (6)
- Brain Networks of Motor Behavior Assessed by Principal Component Analysis (1998) (6)
- tDCS effect on cognitive performance in Parkinson's disease (2016) (6)
- Clinical experience of tolcapone in advanced Parkinson’s disease (2008) (6)
- Incentive-driven decision-making networks in de novo and drug-treated Parkinson's disease patients with impulsive-compulsive behaviors: A systematic review of neuroimaging studies. (2020) (5)
- Opicapone versus placebo in the treatment of Parkinson’s disease patients with end-of-dose motor fluctuation-associated pain: rationale and design of the randomised, double-blind OCEAN (OpiCapone Effect on motor fluctuations and pAiN) trial (2022) (5)
- The Parkinson’s Real-World Impact Assessment (PRISM) Study: A European Survey of the Burden of Parkinson’s Disease in Patients and their Carers (2021) (5)
- Advance Care Planning and Care Coordination for People With Parkinson's Disease and Their Family Caregivers—Study Protocol for a Multicentre, Randomized Controlled Trial (2021) (5)
- Comment on “The Prevalence of Olfactory and Gustatory Dysfunction in COVID-19 Patients: A Systematic Review and Meta-analysis” (2020) (5)
- Impact of Supporting People with Advanced Parkinson’s Disease on Carer’s Quality of Life and Burden (2020) (5)
- Erratum to “Double-blind Randomized Trial of tDCS Versus Sham in Parkinson Patients With Mild Cognitive Impairment Receiving Cognitive Training” Brain Stimulation 8 (2015) 1223–1225 (2016) (5)
- Single photon-emission computed tomography imaging in early Parkinson’s disease (2008) (5)
- Psychometric properties of the Italian version of the Scales for Outcomes in Parkinson's disease- Cognition (SCOPA-Cog). (2013) (5)
- Intrathecal application of autologous bone marrow cell preparations in parkinsonian syndromes (2012) (5)
- Health care for chronic neurological patients after COVID-19 (2020) (5)
- Gender gap in deep brain stimulation for Parkinson’s disease (2022) (5)
- BILATERAL SUBTHALAMIC DEEP BRAIN STIMULATION IN A PATIENT WITH PARKINSON'S DISEASE WHO HAD PREVIOUSLY UNDERGONE THALAMOTOMY AND AUTOLOGOUS ADRENAL GRAFTING IN THE CAUDATE NUCLEUS: CASE REPORT (2006) (5)
- Efficacy, safety and patient’s quality of life of long-term treatment with levodopa-carbidopa intestinal gel in advanced Parkinson’s disease in Romania: Results from GLORIA observational study (2020) (5)
- Cognitive Bizarreness in the Dream and Waking Mentation of Nonpsychotic Patients With Parkinson’s Disease (2010) (4)
- Reduced Effective Connectivity in the Motor Cortex in Parkinson’s Disease (2021) (4)
- Safinamide in the treatment pathway of Parkinson’s Disease: a European Delphi Consensus (2022) (4)
- Cognitive bizarreness in the dream and waking mentation of nonpsychotic patients with Parkinson's disease. (2010) (4)
- Repetitive transcranial magnetic stimulation in the treatment of dystonia (2012) (4)
- Rapid onset of efficacy of rasagiline in early Parkinson’s disease (2013) (4)
- Covid-19 and Parkinson's disease: Acute clinical implications, long-COVID and post-COVID-19 parkinsonism (2022) (4)
- Monitoring of motor and non-motor symptoms of Parkinson's disease through a mHealth platform. (2016) (4)
- The contribution of beta-amyloid to dementia in Lewy body diseases: a 1-year follow-up study (2021) (4)
- Predictors of Response for “Off” Time Improvement With Levodopa-Carbidopa Intestinal Gel Treatment: An Analysis of the GLORIA Registry (2020) (4)
- Remote Evaluation of Parkinson's Disease Using a Conventional Webcam and Artificial Intelligence (2021) (4)
- Risk factors for impulse control disorders and related behaviors in Parkinson’s disease: secondary analyses of the ICARUS study (2019) (4)
- Efficacy of opicapone in different treatment regimens in Parkinson's disease patients with motor fluctuations (2020) (4)
- DBS for Parkinson's disease with behavioural disturbances (2018) (4)
- Patients Stratification Strategies to Optimize the Effectiveness of Scavenging Biogenic Aldehydes: Towards a Neuroprotective Approach for Parkinson's Disease (2021) (4)
- Peripheral neuropathy and levodopa therapy in Parkinson disease: novel insights (2016) (4)
- Oscillatory EEG-TMS Reactivity in Parkinson Disease (2021) (3)
- Long-term safety, discontinuation and mortality in an Italian cohort with advanced Parkinson’s disease on levodopa/carbidopa intestinal gel infusion (2022) (3)
- Regulation of Endoplasmic Reticulum-Mitochondria contacts by Parkin via Mfn2 (2018) (3)
- The epsilon (early Parkinson with L-dopa/DDCi and opicapone) study in early Parkinson's disease: Design and rationale of a phase III, double-blind, randomized, placebo-controlled study (2021) (3)
- Early morning off periods in Parkinson's disease: Characterisation of non motor patterns and treatment effect: An international study (2012) (3)
- Data‐assisted differential diagnosis of dementia by deep neural networks using MRI: A study from the European DLB consortium (2020) (3)
- Altered brain regional homogeneity is associated with depressive symptoms in COVID-19 (2022) (3)
- Psychometric properties of the Italian version of the Scales for Outcomes in Parkinson's disease- Cognition (SCOPA-Cog) (2013) (3)
- Subthalamic deep brain stimulation in Parkinson's disease with SNCA mutations: Based on the follow‐up to 10 years (2022) (3)
- The conundrum of neuroprotection in Parkinson's disease (2011) (3)
- Topography and distribution of adenosine A2A and dopamine D2 receptors in the human Subthalamic Nucleus (2022) (3)
- Does the 5–2-1 criteria identify patients with advanced Parkinson's disease? Real-world screening accuracy and burden of 5–2-1-positive patients in 7 countries (2022) (3)
- Movement perception of the tonic vibration reflex is abnormal in functional limb weakness. (2021) (3)
- Effect of Opicapone on Levodopa Pharmacokinetics in Patients with Fluctuating Parkinson's Disease (2022) (3)
- DN1 ECONOMIC EVALUATIONOF SPECT-DATSCAN IN THE DIAGNOSIS OF PATIENTS WITH CLINICALLY UNCERTAIN PARKINSONISM IN ITALY (2005) (3)
- Revised clinical diagnostic criteria for progressive supranuclear palsy (PSP) (2016) (3)
- The First Parkinson's Disease Pain Questionnaire (King's PD Pain Quest) – an interim analysis of a multicentre study of the patient's perspective (2016) (3)
- Daytime somnolence and night sleep disturbances in Parkinson's disease: background and future treatment prospective (2007) (3)
- Evaluation of Motor Complications: Motor Fluctuations (2012) (3)
- Archeologia del legno. Uso, tecnologia,continuità in una ricerca pluridisciplinare (2011) (3)
- Global Long-Term Registry On Efficacy And Safety Of DUODOPA In Patients With Advanced Parkinson's Disease In Routine Care (GLORIA): 12-Month Interim Findings (S7.005) (2014) (2)
- COVID-19 Neuropathology: evidence for SARS-CoV-2 invasion of Human Brainstem Nuclei (2021) (2)
- Psychometric Properties of Clinical Indicators for Identification and Management of Advanced Parkinson’s Disease: Real-World Evidence From G7 Countries (2022) (2)
- Comparative Effectiveness of Device-Aided Therapies on Quality of Life and Off-Time in Advanced Parkinson’s Disease: A Systematic Review and Bayesian Network Meta-analysis (2022) (2)
- Incidence of Impulsive and Compulsive Behavior Type Adverse Events with Long-term Rotigotine: A Post-hoc Analysis (I3-5E) (2015) (2)
- 2.262 Adherence to antiparkinson medication in a multi-centre European study. (2007) (2)
- Global Long-term Registry on Efficacy and Safety of Levodopa-Carbidopa Intestinal Gel in Patients with Advanced Parkinson’s Disease in Routine Care (GLORIA) - Interim Results in a Subgroup of Patients with Dyskinesia at Baseline (P1.192) (2015) (2)
- MoCA vs. MMSE sensitivity as screening instruments of cognitive impairment in PD, MSA and PSP patients (2016) (2)
- The role of 123I-ioflupane SPECT dopamine transporter imaging in the diagnosis and treatment of patients with dementia with Lewy bodies (2007) (2)
- 2.135 CHARACTERISING NON MOTOR PATTERNS OF EARLY MORNING OFF PERIODS IN PARKINSON'S DISEASE: AN INTERNATIONAL STUDY (2012) (2)
- A novel device in the evaluation of motor impairement in Parkinson Disease (1998) (2)
- CHAPTER 44 - Evaluation of Three Assumptions Regarding Blood—Brain Transport of 6-[ 18 F]Fluoro-L-dopa and O-methyl-dopa in Healthy Volunteers (1996) (2)
- Long-term effectiveness of levodopa-carbidopa intestinal gel on motor and non-motor symptoms in advanced Parkinson’s disease: results of the Italian GLORIA patient population (2020) (2)
- Selecting patients for continuous dopaminergic stimulation therapy (2011) (2)
- Opicapone as an Add-on to Levodopa in Patients with Parkinson’s Disease Without Motor Fluctuations: Rationale and Design of the Phase III, Double-Blind, Randomised, Placebo-Controlled EPSILON Trial (2022) (2)
- Adoption (early levodopa with opicapone in Parkinson's patients with motor fluctuations) study in Parkinson's disease: Design and rationale of a randomized prospective, open-label exploratory trial (2021) (2)
- Pain in Parkinson's disease: Observational study of 225 patients (2011) (2)
- Continuous dopaminergic stimulation in the management of complicated Parkinson's disease. (1988) (2)
- Detection of SARS-CoV-2 viral proteins and genomic sequences in human brainstem nuclei (2023) (2)
- Duodenal alpha-Synuclein Pathology and Enteric Gliosis in Advanced Parkinson's Disease. (2023) (2)
- 1.018 Loss of thalamic serotonin transporters in early-stage, drug-naïve Parkinson's disease patients is associated with tremor: A [123I]β-CIT SPECT study (2007) (2)
- Antiphospholipid‐Related Chorea: Two Case Reports and Role of Metabolic Imaging (2022) (2)
- Gender-related differences in the burden of non-motor symptoms in Parkinson's disease Pablo Martinez-MartinCristian Falup PecurariuPer OdinJacobus J. van Hilten • Angelo AntoniniJose M. Rojo-AbuinVanderci BorgesClaudia Trenkwalder • Dag AarslandDavid J. BrooksKallol Ray Chaudhuri (2012) (2)
- P1.173 Validation of a home environment test battery for status assessment in patients with advanced Parkinson's disease (2009) (2)
- Peri-electrode edema after bilateral subthalamic deep brain stimulation for Parkinson's disease. (2018) (2)
- First clinical trials for neuromotor analysis. (2002) (2)
- A decision support system based on rapid progression rules to enhance baseline evaluation of Parkinson's disease patients (2018) (2)
- Effect of Intensive Rehabilitation Program in Thermal Water on a Group of People with Parkinson’s Disease: A Retrospective Longitudinal Study (2022) (2)
- Clinical, cognitive, and morphometric profiles of progressive supranuclear palsy phenotypes (2023) (2)
- Changes In Troublesome Dyskinesia And Its Relationship With Dose In Advanced Parkinson’s Disease Patients Treated With Levodopa-Carbidopa Intestinal Gel Infusion (P7.071) (2014) (2)
- L’autonomia del diritto della navigazione, il ruolo del diritto comune e la posizione sistematica della legislazione sulla navigazione da diporto (2014) (2)
- Alpha-synuclein pathology and enteric glia in advanced Parkinson's disease: A study from gastrointestinal biopsies (2021) (2)
- 2.258 LONG ACTING DOPAMINE AGONISTS IN CLINICAL PRACTICE: A COMPARATIVE MULTICENTRE EUROPEAN SURVEY IN YOUNG AND OLD PD (2012) (2)
- Dyskinesia Matters: But Not as Much as It Used to (2020) (2)
- Quantification of Brain β-Amyloid Load in Parkinson's Disease With Mild Cognitive Impairment: A PET/MRI Study (2022) (2)
- Il diritto aeronautico a cent'anni dal primo volo (2005) (2)
- Reply to: “Concerns Raised by Publication of Antonini et al., ‘Outcome of Parkinson Disease Patients Affected by Covid‐19’” (2020) (2)
- Non-motor symptoms in Parkinson's Disease (2009) (2)
- Deep brain stimulation into the subthalamic area for Parkinson's disease (2003) (2)
- Confusion of Evidence‐Based Reviews and Guidelines (2023) (1)
- La responsabilità del vettore aereo per il trasporto di persone e cose nella più recente evoluzione normativa: protocolli di Montreal, Varsavia-Montreal, regolamento comunitario (2000) (1)
- Il contratto di ormeggio (1999) (1)
- Brain [52FE]-Transferrin Uptake in Patients with Alzheimer’s Disease and Healthy Subjects: A Positron Emission Tomography (PET) Study (1996) (1)
- Effects of Levodopa-Carbidopa Intestinal Gel on Dyskinesia and Non-Motor Symptoms Including Sleep: Results from a Meta-Analysis with 24-Month Follow-Up (2022) (1)
- Viewpoint and practical recommendations from a movement disorder specialist panel on objective measurement in the clinical management of Parkinson’s disease (2018) (1)
- The Face Behind the Mask: Can Imaging Help Early Parkinson Diagnosis? (2015) (1)
- Management of Parkinson's Disease (2007) (1)
- Correction: A Proposal for a Comprehensive Grading of Parkinson's Disease Severity Combining Motor and Non-Motor Assessments: Meeting an Unmet Need (2016) (1)
- Influence of motor fluctuations duration, levodopa dose and duration of use in efficacy responses of Parkinson's disease patients: Post-hoc analysis from combined BIPARK-I and II (2019) (1)
- Movement disorders: towards new therapies in Parkinson's disease (2012) (1)
- Double-Blind, Double-Dummy, Randomized Study of Continuous Intrajejunal Infusion of Levodopa-Carbidopa Intestinal Gel in Advanced Parkinson's Disease (1)
- Mining motor symptoms UPDRS data of Parkinson's disease patients for the development of Hoehn and Yahr estimation decision support system (2017) (1)
- A study on 3D classical versus GAN-based augmentation for MRI brain image to predict the diagnosis of dementia with Lewy bodies and Alzheimer's disease in a European multi-center study (2022) (1)
- Unraveling depression in Parkinson s disease Depression (2008) (1)
- Editorial: Impulse Control Disorders, Impulsivity and Related Behaviors in Parkinson's Disease (2019) (1)
- Baseline characteristics that influence “off” time improvement in levodopa-carbidopa intestinal gel-treated advanced Parkinson’s disease patients in the GLORIA registry (2017) (1)
- Corrigendum to "Global long-term study on motor and non-motor symptoms and safety of levodopa-carbidopa intestinal gel in routine care of advanced Parkinson's disease patients; 12-month interim outcomes" [Parkinsonism Relat. Disord. 21(3) (2015) 231-235]. (2016) (1)
- Influence of disease severity in the efficacy response of Parkinson's disease patients with motor fluctuations: Post-hoc analysis from combined BIPARK-I and II (2019) (1)
- Reply to: “Parkinson disease‐associated dyskinesia in countries with low access to levodopa‐sparing Regimens“ (2019) (1)
- [Duodenale levodopa and apomorphine infusion for motor complications in advanced Parkinson's disease]. (2018) (1)
- Corrigendum to “Early detection of wearing off in Parkinson disease: The DEEP study” [Parkinsonism Relat Disorder 20 (2014) 204–211] (2015) (1)
- Impact of advanced Parkinson’s disease on caregivers: an international real-world study (2023) (1)
- Efficacy of opicapone in Parkinson’s disease patients according to baseline presence of dyskinesia: A post-hoc analysis from combined BIPARK-I and II (2019) (1)
- TaSCA, an Agile Survey on Chemosensory Impairments for Self-Monitoring of COVID-19 Patients: A Pilot Study (2021) (1)
- Design and development of a mobile application to explore cognitive skills in parkinson’s disease patients (2016) (1)
- Personalized Care in Late-Stage Parkinson’s Disease: Challenges and Opportunities (2022) (1)
- Erratum to: Validation of the Italian version of Parkinson’s Disease-Cognitive Rating Scale (PD-CRS) (2015) (1)
- Global Long-Term Registry on Efficacy and Safety of Levodopa-Carbidopa Intestinal Gel in Patients with Advanced Parkinson’s Disease in Routine Care (GLORIA) - Interim Results on Non-Motor Symptoms (I3-3B) (2015) (1)
- Action Selection and Motor Decision Making: Insights from Transcranial Magnetic Stimulation (2022) (1)
- [Chronic subthalamus stimulation for the treatment of Parkinson's disease. Analysis of results by classes of symptoms and adverse effects]. (2003) (1)
- The rediscovery of levodopa in the treatment of Parkinson's disease [La riscoperta della levodopa nella terapia della malattia di Parkinson] (2003) (0)
- Optimizing levodopa therapy, when and how? Perspectives on the importance of delivery and the potential for an early combination approach (2023) (0)
- Subject Index Vol. 38,1997 (1997) (0)
- Multicenter experience of mixed deep brain stimulation implants for movement disorders (2016) (0)
- Sex differences in brain atrophy in dementia with Lewy bodies (2023) (0)
- Correlation between regional cerebral perfusion and motor function in patients with Parkinson's disease and extradural motor cortex stimulation (2008) (0)
- Spect imaging biomarkers (2009) (0)
- Longitudinal study of FP-CIT and ECD SPECT in Parkinson's disease and essential tremor (2009) (0)
- Efficacy of opicapone according to levodopa's duration of use in Parkinson's disease patients with motor fluctuations (2021) (0)
- Clinical utility of DaTscan in patients with suspected Parkinsonian syndrome: a systematic review and meta-analysis (2021) (0)
- Gender gap in deep brain stimulation for Parkinson’s disease (2022) (0)
- Combining Transcranial Magnetic Stimulation and Deep Brain Stimulation: Current Knowledge, Relevance and Future Perspectives (2023) (0)
- ----------------------------------------------------------------------------------------------------------------------------- - (2017) (0)
- Randomized, Double-Blind, Double-Dummy Study of Levodopa-Carbidopa Intestinal Gel in Patients with Advanced Parkinson's Disease: Efficacy Analyses by Subgroups (S23.003) (2013) (0)
- 1.304 THE ANATOMICAL CORRELATES OF FREEZING OF GAIT IN PARKINSON'S DISEASE (2012) (0)
- The relationship between artistic productivity, impulse control and frontal lobe function in Parkinson’s disease. (2008) (0)
- P.17.14 PERCUTANEOUS ENDOSCOPIC GASTROJEJUNOSTOMY (PEGJ) FOR CONTINUOUS LEVODOPA DELIVERY FOR THE TREATMENT OF COMPLICATED PARKINSON'S DISEASE: A SIX YEARS EXPERIENCE (2013) (0)
- Education on palliative care for Parkinson patients: development of the “Best care for people with late-stage Parkinson’s disease” curriculum toolkit (2021) (0)
- Lisuride and [C-11]-Raclopride Interaction at the D2 Receptor Site (1995) (0)
- Movement Disorders in Neurologic and Systemic Disease: Movement disorders in multiple sclerosis (2012) (0)
- Parkinson's Disease and cognitive reserve (2016) (0)
- Dibattito - 4 settembre 1994 (1995) (0)
- Confusion of evidence‐based reviews and guidelines (2023) (0)
- Oral session 9—Parkinson's disease (1) (2005) (0)
- A multicenter epidemiological and clinical study on deep brain stimulation (DBS) for Parkinson's disease: The pilot study* (2016) (0)
- Rationale and Design of an Open-Label, Randomized, 26-Week Study Comparing Levodopa-Carbidopa Intestinal Gel to Optimized Medical Treatment on Non-Motor Symptoms in Patients with Advanced Parkinson’s Disease – INSIGHTS Study (P2.048) (2018) (0)
- Genomic surveillance of SARS-CoV-2 in patients presenting neurological manifestations (2022) (0)
- An analysis of cognitive and behavioral features of MSA-P and MSA-C patients. (2010) (0)
- Opicapone's added benefit as a first-line adjunctive therapy to levodopa and when used promptly for motor fluctuations in Parkinson's disease (2020) (0)
- PINK1 mutations cause typical late-onset Parkinson's disease as well as early-onset Parkinsonism. (2006) (0)
- The role of continuous dopaminergic stimulation in the management of non-motor symptoms in Parkinson’s disease (2014) (0)
- The role of 123 Iio fl upane SPECT dopamine transporter imaging in the diagnosis and treatment of patients with dementia with Lewy bodies (2007) (0)
- Non-motor Symptoms (NMS) Improvement is Positively Correlated with Baseline NMS Burden and Improved Quality of Life in Advanced Parkinson’s Disease Patients Treated with Levodopa-carbidopa Intestinal Gel: A Post-hoc Analysis from the GLORIA Registry (P1.038) (2018) (0)
- 2.362 NEUROMUSCULAR TAPING FOR THE TREATMENT OF DROP HEAD SYNDROME IN MULTISYSTEM ATROPHY (2012) (0)
- 2.214 Tolcapone treatment fluctuating patients with Parkinson's disease who did not benefit from entacapone (2007) (0)
- New Section: 'What Is Your Diagnosis?' (1997) (0)
- Non-motor predictors of 36-month quality of life after subthalamic stimulation in Parkinson disease (2021) (0)
- Non-motor symptoms (NMS)in parkinsonism: preliminary results of the PRIAMO(Parkinson and non-motor symptoms)study (2006) (0)
- Extradural motor cortex stimulation effect on brain function in patients with Parkinson's disease (2007) (0)
- Abstracts of the 6th international multiple system atrophy congress (2018) (0)
- Gastrointestinal Safety of Levodopa-Carbidopa Intestinal Gel in Advanced Parkinsonʼs Disease Patients: Interim Results From the GLORIA Long-Term Registry: 1462 (2015) (0)
- PNL16 THE ECONOMIC BURDEN OF PARKINSONISM IN ITALY (2005) (0)
- Forum Report ミラペックスLA発売2周年記念講演会 New Thinking on Treatment Strategies for Parkinson's Disease : Continuous Drug Delivery : Clinically relevant or just a theoretical concept? (2013) (0)
- 2.220 Duodenal levodopa infusion for advanced Parkinson's disease: 24-month treatment outcome (2007) (0)
- Beneficial nonmotor effects of subthalamic and pallidal DBS in Parkinson's disease (2018) (0)
- Modulation of motor vigour by expectation of reward probability trial-by-trial is preserved in healthy ageing and Parkinson’s disease patients (2022) (0)
- Impulsivity andcompulsivity in drug-naïve patients with Parkinson's disease (2011) (0)
- Determination of minimal important difference thresholds for Parkinson’s disease Questionnaire-39 in advanced Parkinson’s disease patients (2016) (0)
- Olanzapine reduces levodopa-related dyskinesias in patients with Parkinson's disease (1999) (0)
- Case Studies on Stalevo (2009) (0)
- Artistic productivity in Parkinson’s disease (2009) (0)
- 1.270 Loss of thalamic serotonin transporters in early-stage, drug-naïve Parkinson's disease patients is associated with tremor: A [123I]β-CIT SPECT study (2007) (0)
- A Long-term Study on Effectiveness of Levodopa-carbidopa Intestinal Gel Treatment in Advanced Parkinson’s Disease Patients (P5.066) (2018) (0)
- Acknowledgment to Referees (2016) (0)
- 2.030 PATTERNS OF CORTICAL AND SUB-CORTICAL THINNING IN PARKINSON'S DISEASE (2012) (0)
- Subtalamic DBS for Parkinson's disease under general anesthesia: clinical results compared with awake surgery (2011) (0)
- Focus on Diabetic Retinopathy (DR) and MicroRNA “What Association” (2021) (0)
- PET evaluation of dopamine transporters in early and late onset patients with Parkinson's disease (2001) (0)
- Preservation of the nigrostriatal function in a group of patients with corticobasal degeneration: evidence from a three-centre FP-CIT SPECT study. (2008) (0)
- Functional neuroimaging (ECD/SPECT and 1.5 T MRI) in the differential diagnosis between MSA and Parkinson's disease (PD) (1999) (0)
- Challenges in advanced treatments in Parkinson's disease (2021) (0)
- Modulation of Motor Vigor by Expectation of Reward Probability Trial-by-Trial Is Preserved in Healthy Ageing and Parkinson's Disease Patients (2023) (0)
- Gli operatori aeroportuali : competenze e responsabilità : atti del convegno Modena, 9 maggio 1996 (1996) (0)
- Levodopa Dose Equivalency in Parkinson's Disease: Updated Systematic Review and Proposals. (2023) (0)
- Smell deficits in COVID-19 and possible links with Parkinson's disease (2022) (0)
- Fractal Analysis of Lower Back Acceleration Profiles in balance tasks (2021) (0)
- Neurocognitive correlates of numerical abilities in Parkinson’s disease (2022) (0)
- Italian survey on intraduodenal levodopa gel treatment in advanced Parkinson disease: State of the art 10 years after marketing (2016) (0)
- Study design to assess the effect of opicapone on levodopa pharmacokinetics in different levodopa-optimized treatment regimens in Parkinson's disease patients (2021) (0)
- SPECT Imaging in Movement Disorders (2010) (0)
- The ocean (opicapone effect on motor fluctuations and associated pain) study in Parkinson's disease: Design and rationale of a randomized double-blind placebo-controlled trial (2021) (0)
- Relationship between I123-Ioflupane binding in striatal dopamine transporters and depression in Parkinson's disease: A SPECT study (2007) (0)
- Early Compensatory Mechanisms in LRRK2 Mutation Carriers (2022) (0)
- New routes of dopaminergic drug delivery in patients with Parkinson's disease (2019) (0)
- Impact of Supporting People with Advanced Parkinson’s Disease on Carer’s Quality of Life and Burden [Corrigendum] (2021) (0)
- Pathology of Vessels Supplying the Brain in Patients with Parkinson’s Disease (2011) (0)
- Long-term Outcome of Duodenal Levodopa Infusion for Advanced Parkinson ’ s Disease (2008) (0)
- Gastrointestinal safety of levodopa-carbidopa intestinal gel in advanced Parkinson's disease patients: GLORIA long-term registry interim results (2016) (0)
- Tremor UPDRS estimation in home environment. (2016) (0)
- Utilization of COMT inhibitors, dopamine agonists, and MAO-B inhibitors with levodopa-carbidopa instestinal gel in advanced Parkinson's disease patients: Summary of phase 3 and real-world studies (2019) (0)
- Correction to: The TANDEM investigation: efficacy and tolerability of levodopa-carbidopa intestinal gel in (LCIG) advanced Parkinson’s disease patients (2020) (0)
- Prospective role of PAK6 and 14-3-3γ as biomarkers for Parkinson’s disease (2023) (0)
- 123I-Ioflupane striatal binding in PARK8 and PARK2-linked Parkinson’s disease: A SPECT comparative study (2006) (0)
- Deep brain stimulation in Parkinson's disease: pharmacoeconomics and health care policies (2006) (0)
- Striatal patterns of DAT density in patients with essential tremor (ET): A prospective I-123 FP-CIT SPECT study (2008) (0)
- Review for "Comparison between four published definitions of hyposmia in Parkinson's disease" (2020) (0)
- 2.19.1 TARGETING UNMET NEEDS IN PARKINSON'S DISEASE: CONTINUOUS DOPAMINERGIC STIMULATION THERAPY (2012) (0)
- The safety/tolerability of opicapone when used early in Parkinson's disease patients with levodopa-induced motor fluctuations: A post-hoc analysis of BIPARK-I and II (2022) (0)
- Bilateral subthalamic stimulation improves aspects of nonmotor symptoms in Parkinson’s disease (2014) (0)
- La tutela giuridica del nome di dominio (2001) (0)
- Preservation of the nigro-striatal function in a group of patients with a clinical diagnosis of corticobasal degeneration: evidence from a three-centre FP-CIT SPECT study (2007) (0)
- Neutral Amino Acids Influence [ 18 F]Fluorodopa Quantification (1998) (0)
- Peripheral nervous system involvement in Parkinson's disease: Evidence and controversies Parkinsonism and Related Disorders (0)
- Parkinson's disease severity levels and MDS-Uni fi ed Parkinson's Disease Rating Scale Parkinsonism and Related Disorders (0)
- The impact of neuropsychiatric symptoms on quality of life in Parkinson’s disease (2010) (0)
- Levodopa-carbidopa intestinal gel treatment in patients with <10 years of Parkinson's disease: GLORIA registry interim results (2016) (0)
- EP 9. GPi Deep Brain Stimulation for the treatment of status distonicus in tardive dystonia (2016) (0)
- The reliability of a deep learning model in external memory clinic MRI data: A multi‐cohort study (2020) (0)
- Multifocal alterations of white matter accompany the transition from normal cognition to dementia in Parkinson’s disease patients (2018) (0)
- Distribution and impact on quality of life of the pain modalities assessed by the King’s Parkinson’s disease pain scale (2017) (0)
- 1.108 DEEP STUDY: A LARGE EPIDEMIOLOGICAL SURVEY ABOUT WEARING OFF IN PARKINSON DISEASE (2012) (0)
- Double-blind randomized trial of t-DCS versus sham in Parkinson patients with mild cognitive impairment receiving cognitive training, Brain Stimulation (2015), doi: 10.1016/j.brs.2015.07.043 (2015) (0)
- Satellite Symposia (2011) (0)
- Reply to: “Experience with a New Index to Differentiate Parkinson's Disease and Progressive Supranuclear Palsy” (2021) (0)
- Responsabilità contrattuale e responsabilità extraconttratuale: il diritto dei trasporti, banco di prova di una adeguata evoluzione del regime del concorso (2010) (0)
- Development of new treatments for Batten disease (2014) (0)
- 123I-Ioflupane-SPECT assessment of minor abnormalities in striatal dopamine transporter density (SDAT) in familial and non-familial essential tremor (2006) (0)
- Access Through Partnership A Stakeholder Dialogue (2012) (0)
- Anatomical profile of cognitive impairment in MSA (2016) (0)
- 1.164 Psychiatric symptoms in Parkinson's disease: An assessment in 486 Italian patients (2007) (0)
- Patient-centred management of Parkinson's disease (2020) (0)
- Spotlight on non-motor symptoms and Covid-19 (2022) (0)
- O.058 Will continuous dopamine stimulation prevent motor complications (2009) (0)
- Opicapone as first-line adjunctive levodopa treatment in Parkinson's disease patients with motor fluctuations: BIPARK-I and II combined post-hoc analysis (2020) (0)
- Relationship between isolated mixed tremor and Parkinson’s disease: results from a 123I FP-CIT SPECT and clinical follow-up study (2006) (0)
- Characteristics, treatment patterns and disease burden of people with Parkinson's disease in the Parkinson's disease real-world impact assessment (PRISM) study (2020) (0)
- Effects of Levodopa-Carbidopa Intestinal Gel Compared with Optimized Medical Treatment on Nonmotor Symptoms in Advanced Parkinson's Disease: INSIGHTS Study (2022) (0)
- Content validity of MANAGE-PD tool: Real-world evidence from PD patients in G7 countries (2020) (0)
- Author Response. (2013) (0)
- What you always wanted to know about … The newest therapeutical strategies (2007) (0)
- c-Rel deficient mice, a mouse model of “spreading” PD-like pathology (2016) (0)
- Non-motor symptoms (nms) improvement is correlated with baseline nms burden and improved quality of life (QoL) in levodopa-carbidopa intestinal gel (LCIG) treated parkinson’s disease patients (2017) (0)
- Poster Presentations (2023) (0)
- NF-κB/c-Rel DNA-binding is reduced in substantia nigra and peripheral blood mononuclear cells of Parkinson's disease patients (2023) (0)
- Pharmacological strategies for controlling motor fluctuations in Parkinson's disease. (1988) (0)
- L'attività di trasporto aereo dopo la liberalizzazione del cabotaggio (1998) (0)
- Long-term changes of striatal dopamine D-2 receptors in Parkinsons disease studied with PET and raclopride (1996) (0)
- Dai tipi legali ai modelli sociali nella contrattualistica della navigazione, dei trasporti e del turismo : atti del convegno Modena, 31 marzo e 1 aprile 1995 (1996) (0)
- Il nuovo diritto aeronautico (2002) (0)
- I contratti di utilizzazione dell'aeromobile (2006) (0)
- Feasibility and Utility of mHealth for the Remote Monitoring of Parkinson Disease: Ancillary Study of the PD_manager Randomized Controlled Trial (Preprint) (2019) (0)
- Le assicurazioni relative al trasporto di merci su strada (1996) (0)
- L'attività di trasporto aereo dopo la liberalizzazione del cabotaggio : atti del convegno, Modena, 4 aprile 1997 (1998) (0)
- Il nuovo ruolo dell'aeroporto (1995) (0)
- Il Noleggio di aeromobile (2011) (0)
- Correction to: Long-term safety, discontinuation and mortality in an Italian cohort with advanced Parkinson’s disease on levodopa/carbidopa intestinal gel infusion (2022) (0)
- Il noleggio nell'ambito dei contratti di utilizzazione della nave (2006) (0)
- Dibattito - 5 settembre (1995) (0)
- Vecchi e nuovi spunti solutivi del problemi giuridici del trasporto a mezzo container (1997) (0)
- KARATE AND AUTISM SPECTRUM DISORDERS: SPORT AS TREATMENT FOR SOCIAL COGNITION DEFICITS (2008) (0)
- La navigazione da diporto : le infrastrutture, l'organizzazione, i contratti e le responsabilità : atti del convegno, Trieste, 27 marzo 1998 (1999) (0)
- DOTTRINA - Il trasporto multimodale: regime normativo e responsabilità del vettore. (2009) (0)
- NOTE ED OSSERVAZIONI A SENTENZE. Le inchiese sugli incidenti aereri (1991) (0)
- Navigazione da diporto e istituti del diritto della navigazione (2017) (0)
- Il risarcimento del danno alla persona nel trasporto aereo: contenuto e soggetti dell'obbligazione risarcitoria (2000) (0)
- LA DISCIPLINA DEL TRASPORTO DI COSE: PRESENTE E FUTURO. TAVOLA ROTONDA - GENOVA 2-3 FEBBRAIO 2001. La responsabilità del vettore marittimo di cose nel progetto di modifica della normativa internazionale uniforme (2001) (0)
- Dibattito 4 settembre (1996) (0)
- Characterizing a Parkinson’s Disease Population Inadequately Controlled by Oral Therapy: Baseline Characteristics of the Phase 3 Clinical Program for Foslevodopa/Foscarbidopa (P2-11.006) (2023) (0)
- CRONACHE E NOTE. Il "feederaggio" e la liberalizzazione del cabotaggio comunitario (1998) (0)
- Poor Reactivity of Posterior Electroencephalographic Alpha Rhythms During the Eyes Open Condition in Patients with Dementia Due to Parkinson’s Disease (2022) (0)
- 2.256 SYMPTOMATIC NEUROPATHY IN PARKINSON'S DISEASE PATIENTS DURING DUODENAL LEVODOPA INFUSION TREATMENT (2012) (0)
- NOTE ED OSSERVAZIONI A SENTENZA.- Brevi note in tema di differenziazione della fattispecie del ricupero da quella del salvataggio ed identificazione del debitore del compenso (1996) (0)
- La responsabilità del vettore aereo di persone ne transporto nazionale e in quello internazionale (2000) (0)
- L'attività di navigazione interna, rilevanza economica e profili giuridici : atti del convegno, Mantova, 26 marzo 1999 (2000) (0)
- LE BATTERIE A IONI LITIO : FONTI DI ENERGIA PER L'ELETTRONICA PORTATILE (1998) (0)
- La responsabilità nella gestione delle infrastrutture della naviagazione marittima e aerea. (2015) (0)
- Acknowledgement to Referees (2014) (0)
- Managing for the Long-term – Strategies for Initiating and Maintaining Successful Continuous Dopaminergic Stimulation Treatment (2012) (0)
- Correction to: Caregiver burden and its related factors in advanced Parkinson’s disease: data from the PREDICT study (2020) (0)
- Erratum to: The status of olfactory function and the striatal dopaminergic system in drug-induced parkinsonism (2010) (0)
- Reply: Dynamic functional connectivity changes in Lewy body disease. (2019) (0)
- 4-30-03 [C11] Racloprid and pet in patients with dopa responsive dystonia and Parkinson's disease (1997) (0)
- Non-motor effects of deep brain stimulation in Parkinson's disease motor subtypes. (2023) (0)
- 2.7.3 PULSATILE OR CONTINUOUS DOPAMINOMIMETIC STRATEGIES (2012) (0)
- 1.166 Diagnosis of personality structure and cognition in patients with Parkinson's disease (2007) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Angelo Antonini?
Angelo Antonini is affiliated with the following schools:
